Nov 30, 2021 / 02:15PM GMT
Joshua Elliott Schimmer - Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst
All right. Welcome, everyone, for the Regeneron session at Evercore ISI Healthcare Conference. I think Mark is going to kick us off with some quick commentary, and we are going to dive into a bunch of exciting topics, cover as much ground as we can in 20 minutes.
Mark Hudson - Regeneron Pharmaceuticals, Inc. - IR Executive
Great. Thanks, Josh, and it's great to be here. And good morning, good afternoon, everyone, joining us on today's webcast. So I'm Mark Hudson from the IR team. And joining me today is Neil Stahl and Jamie Orengo, both key scientists and R&D leaders here at Regeneron. So Neil is our Executive Vice President of R&D and one of the founding fathers of Regeneron with nearly 30 years plus at the company. And he's instrumental in some of the key technologies and ultimately, some of the drugs discovered and developed in our labs in New York. And Jamie is a VP of Research of Allergy & Immunity and one of the lead scientists and
Regeneron Pharmaceuticals Inc at Evercore ISI HealthCONx Virtual Conference Transcript
Nov 30, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers